Ophthalmoplegia Market Report 2026

The ophthalmoplegia market size has grown rapidly in recent years. It will grow from $1.84 billion in 2025 to $2.03 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to limited treatment options for ophthalmoplegia, lack of specialized ophthalmic centers, low awareness of eye muscle disorders, reliance on conventional surgical approaches, increasing prevalence of neuromuscular disorders affecting eyes.

The ophthalmoplegia market size is expected to see strong growth in the next few years. It will grow to $2.95 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in minimally invasive surgical techniques, growth of targeted pharmacological therapies, rising tele-ophthalmology adoption, increasing government initiatives for rare eye disorder management, growth in personalized medicine and genetic diagnostics. Major trends in the forecast period include increasing adoption of minimally invasive ophthalmoplegia surgeries, rising use of targeted drug therapies for eye muscle disorders, growing focus on early diagnosis and screening, expansion of tele-ophthalmology for patient monitoring, rising awareness about neurological and muscular eye conditions.

The rising incidence of neurological disorders is expected to drive growth in the ophthalmoplegia market in the coming years. Neurological disorders are medical conditions affecting the nervous system, including the brain, spinal cord, and nerves, and often cause symptoms such as muscle weakness, coordination difficulties, and cognitive impairments. This increase is influenced by genetic predisposition, making some individuals more susceptible to conditions like Alzheimer's and Parkinson's disease, as well as lifestyle factors such as poor diet, sedentary behavior, and chronic stress, which contribute to neurodegeneration and impaired brain function. Ophthalmoplegia assists in diagnosing neurological disorders, including Alzheimer's disease, multiple sclerosis, and stroke, by indicating impaired eye muscle control that reflects underlying nervous system dysfunction. For example, in March 2023, according to the Alzheimer's Association, a US-based nonprofit, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections suggesting this number could rise to 13.8 million by 2060. The increasing prevalence of neurological disorders is therefore driving the ophthalmoplegia market.

The growing prevalence of autoimmune conditions is also expected to boost the ophthalmoplegia market. Autoimmune conditions occur when the immune system mistakenly attacks the body's own healthy cells, causing inflammation and tissue damage. Certain genetic variants can trigger an overactive immune response, making individuals more prone to these conditions. Environmental factors such as infections, stress, and lifestyle habits further contribute to their rising incidence. Ophthalmoplegia, when associated with autoimmune disorders, helps identify underlying immune dysfunction, enabling targeted treatments that address both eye muscle paralysis and the root autoimmune condition. For example, in March 2023, according to the Society for Women’s Health Research, a US-based nonprofit organization, autoimmune diseases were estimated to affect 23.5 to 50 million people, with global rates increasing by 3-9% annually. This rising prevalence is driving the growth of the ophthalmoplegia market.

Increasing cases of head injuries and trauma are expected to support the growth of the ophthalmoplegia market. Head injuries or trauma include any damage to the scalp, skull, or brain caused by external forces such as falls, accidents, or impacts. The rise in these cases is linked to factors like increasing road accidents, where high-speed collisions, lack of helmet use, and reckless driving elevate the risk of severe head trauma. Workplace accidents, falls, sports injuries, and violence also contribute to the growing incidence of traumatic brain injuries. Ophthalmoplegia is useful in assessing head injuries by revealing potential neurological damage through impaired eye movement, allowing for early diagnosis and intervention. For example, in 2023, a report by the Wisconsin Department of Health Services, a US-based government agency, noted that traumatic injuries caused by assault increased by 3% compared to 2022, rising from 1,544 cases to 1,584 cases. These rising incidences of head injuries are driving growth in the ophthalmoplegia market.

Major companies operating in the ophthalmoplegia market are Hoffmann‑La Roche Ltd., AbbVie Inc., Novartis AG., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Bayer AG., Santen Pharmaceutical Co. Ltd., Oculis Holding AG., Clearside Biomedical Inc., ViGeneron GmbH, GenSight Biologics SA, EyeBio Inc., Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Eli Lilly and Company, Bristol‑Myers Squibb, Amgen Inc., Vertex Pharmaceuticals Inc., Acorda Therapeutics Inc., Biogen Inc., NicOx S.A.

North America was the largest region in the ophthalmoplegia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ophthalmoplegia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ophthalmoplegia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the ophthalmoplegia market by increasing the cost of imported surgical instruments, medications, and diagnostic equipment. Hospitals, clinics, and ambulatory centers in regions like north america, europe, and asia-pacific face the most significant effect due to dependence on foreign ophthalmic technologies. Positive effects include the encouragement of local manufacturing, investment in domestic production of ophthalmoplegia treatment tools, and the acceleration of innovation in minimally invasive procedures and drug therapies.

The ophthalmoplegia market research report is one of a series of new reports that provides ophthalmoplegia market statistics, including ophthalmoplegia industry global market size, regional shares, competitors with a ophthalmoplegia market share, detailed ophthalmoplegia market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmoplegia industry. This ophthalmoplegia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ophthalmoplegia is the paralysis or weakness of one or more muscles that control eye movement. It can affect voluntary or involuntary eye movements and may result from neurological disorders, muscle diseases, or vascular conditions.

The main types of ophthalmoplegia include external ophthalmoplegia and internuclear ophthalmoplegia. External ophthalmoplegia involves paralysis or weakness of the extraocular muscles, leading to impaired eye movement and drooping eyelids. Treatment options include surgery or drug therapy, and these services are used by end users such as hospitals, clinics, and ambulatory care centers.

The ophthalmoplegia market consists of revenues earned by entities by providing services such as diagnosis and imaging services, neurological and ophthalmic evaluations, genetic testing and counselling, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The ophthalmoplegia market also includes sales of eye patches and prisms, neuromuscular electrical stimulation (NMES) devices, corticosteroids, immunosuppressants, and botulinum toxin injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.